石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

未开盘 05-06 16:08:10

2.380

-0.030

-1.24%

最高2.400	最低2.350	成交量578.49万
今开2.350	昨收2.410	日振幅2.07%
总市值69.00亿	流通市值69.00亿	总股本28.99亿
成交额1,373万	换手率0.20%	流通股本28.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":2.38,"timestamp":1778054890006,"preClose":2.41,"halted":0,"volume":5784856,"delay":0,"changeRate":-0.01244813278008309,"floatShares":2899000000,"shares":2899000000,"eps":0.1605,"marketStatus":"未开盘","change":-0.03,"latestTime":"05-06 16:08:10","open":2.35,"high":2.4,"low":2.35,"amount":13730007,"amplitude":0.020747,"askPrice":2.38,"askSize":18000,"bidPrice":2.37,"bidSize":204000,"shortable":3,"etf":0,"ttmEps":0.1605,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778117400000},"marketStatusCode":0,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.41,"dividendRate":0.033613,"openAndCloseTimeList":[[1778031000000,1778040000000],[1778043600000,1778054400000]],"volumeRatio":0.8932209252260489,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005/tweets","defaultTab":"tweets","newsList":[{"id":"1118440548","title":"石四药集团全量程C反应蛋白检测试剂盒等产品获河北省药监局医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=1118440548","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118440548?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:50","pubTimestamp":1778057441,"startTime":"0","endTime":"0","summary":"石四药集团宣布，其全量程C反应蛋白检测试剂盒及其他配套试剂盒已正式获得河北省药品监督管理局颁发的医疗器械注册证书。这一重要资质的取得，标志着公司相关产品符合国家医疗器械市场准入标准，为后续商业化推广奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633970154","title":"石四药集团(02005)取得甲磺酸多沙唑嗪缓释片(4mg)等药品的生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2633970154","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633970154?lang=zh_cn&edition=full","pubTime":"2026-05-06 12:20","pubTimestamp":1778041210,"startTime":"0","endTime":"0","summary":"本集团已取得国家药监局有关甲磺酸多沙唑嗪缓释片的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。诚如本公司日期为2024年4月8日的公告所载，本集团的甲磺酸多沙唑嗪塬料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)取得甲磺酸多沙唑嗪缓释片(4mg)等药品的生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157696322","title":"石四药集团4月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1157696322","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157696322?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:39","pubTimestamp":1777883993,"startTime":"0","endTime":"0","summary":"2026年5月4日，石四药集团有限公司公布截至2026年4月30日止的股份变动月报表。报告显示，公司本月未发生新增发行、购回或注销股份等变动，整体股本保持稳定。根据公告，截至2026年4月30日，石四药集团法定注册股本为10,000,000,000股，面值每股港币0.02元，总额约为港币200,000,000，较上月保持不变。同时，公司于2023年1月13日采纳的二零二三年购股权计划对应的股份期权数量维持不变，本月底有最多297,268,338股可于未来行使。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632939901","title":"石四药集团(02005)一季度股东应占溢利约1.71亿港元 同比增加1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632939901","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632939901?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:38","pubTimestamp":1777883884,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布截至2026年一季度经营业绩，集团截至2026年3月31日止3个月的未经审核营业额约12.27亿港元，同比增加8.0%;毛利约5.02亿港元，同比减少1.3%，其未经审核毛利率约为41.0%，同比减少3.8百分点。截至2026年3月31日止3个月，集团的未经审核公司股东应占溢利约171,206,000港元，同比增加1.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630359103","title":"石四药集团(02005)取得国家药监局有关注射用盐酸地尔硫䓬(10mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2630359103","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630359103?lang=zh_cn&edition=full","pubTime":"2026-04-27 12:04","pubTimestamp":1777262692,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布公告，集团已取得中国国家药监局有关注射用盐酸地尔硫的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。注射用盐酸地尔硫主要用于室上性心动过速、手术时异常高血压的急救处置、高血压急症及不稳定心绞痛。盐酸普萘洛尔注射液主要用于控制室上性快速心律失常及室性心律失常、劳力型心绞痛及嗜铬细胞瘤。集团的盐酸普萘洛尔原料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)取得国家药监局有关注射用盐酸地尔硫䓬(10mg)的药品生产注册批件","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629308192","title":"石四药集团：2025年净利润4.71亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629308192","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629308192?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:02","pubTimestamp":1776762129,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月21日，石四药集团（02005.HK）公告，截至二零二五年十二月三十一日止年度，公司总收益为41.65亿港元，同比下降27.8%；年内溢利为4.71亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604213712364659.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604213712364659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629086028","title":"石四药集团(02005)：呋塞米获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2629086028","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629086028?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:32","pubTimestamp":1776760377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，本集团的呋塞米已获中国国家药品监督管理局(国家药监局)批准登记成为在上市制剂使用的原料药。诚如本公司日期分别为2025年6月30日及2024年12月27日的公告所载，本集团已取得国家药监局有关呋塞米片及呋塞米注射液的药品生产注册批件。呋塞米主要用于治疗各种水肿性疾病、高血压、高钾血症及高钙血症、稀释性低钠血症、抗利尿激素分泌过多症(SIADH)及急性药物毒物中毒(如巴比妥类药物中毒)，及预防急性肾功能衰竭。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","LU2460026573.USD","IPOS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626630561","title":"石四药集团(02005)：取得复方电解质醋酸钠葡萄糖注射液 (250ml 及500ml)和盐酸甲氧氯普胺注射液(2ml:10mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2626630561","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626630561?lang=zh_cn&edition=full","pubTime":"2026-04-10 12:13","pubTimestamp":1775794404,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布公告，集团已取得中国国家药品监督管理局有关复方电解质醋酸钠葡萄糖注射液 和盐酸甲氧氯普胺注射液的药品生产注册批件，均属于化学药品第 3类，视同通过一致性评价。复方电解质醋酸钠葡萄糖注射液主要用于不能口服给药或口服给药不能充分摄取时，补充和维持水分及电解质，并补给能量。集团的盐酸甲氧氯普胺原料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)：取得复方电解质醋酸钠葡萄糖注射液 (250ml 及500ml)和盐酸甲氧氯普胺注射液(2ml:10mg)的药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177409972","title":"石四药集团产品线涵盖复方电解质、醋酸钠葡萄糖注射液及盐酸甲氧氯普胺注射液","url":"https://stock-news.laohu8.com/highlight/detail?id=1177409972","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177409972?lang=zh_cn&edition=full","pubTime":"2026-04-10 12:05","pubTimestamp":1775793914,"startTime":"0","endTime":"0","summary":"石四药集团的核心产品组合包含复方电解质注射液、醋酸钠葡萄糖注射液以及盐酸甲氧氯普胺注射液等重要医药制剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108828105","title":"石四药集团3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1108828105","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108828105?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:26","pubTimestamp":1775035584,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年4月1日发布的股份变动月报表显示，截至2026年3月31日，公司法定及注册股本数额维持在10,000,000,000股，面值0.02港元，折合注册股本总额2亿港元，报告期内未发生增减变动。报告指出，公司已符合香港联交所上市规则所要求的最低公众持股量，并确认当月所有股份及库存股的发行、持有或转让事宜均履行必要法定程序及监管规定。该月报表由执行董事兼公司秘书周兴扬签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623753393","title":"石四药集团(02005)：乌帕替尼已获中国药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2623753393","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623753393?lang=zh_cn&edition=full","pubTime":"2026-03-31 09:12","pubTimestamp":1774919552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的乌帕替尼已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药，是国内企业第三家获批。乌帕替尼是一种JAK-1抑制剂，主要用于治疗类风湿性关节炎和克罗恩病，特应性皮炎类、银屑病关节炎、溃疡性结肠炎、巨细胞动脉炎等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)：乌帕替尼已获中国药监局批准登记成为在上市制剂使用的原料药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146462165","title":"石四药集团乳酸钠林格冲洗液及布美他尼注射液获国家药监局生产与注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1146462165","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146462165?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:25","pubTimestamp":1774607112,"startTime":"0","endTime":"0","summary":"石四药集团宣布，其两款药品——乳酸钠林格冲洗液和布美他尼注射液，已正式获得中国国家药品监督管理局（NMPA）颁发的药品生产批准与注册批件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622684099","title":"石四药集团(02005)取得国家药监局有关乳酸钠林格冲洗液(3000ml)和布美他尼注射液 (2ml:1mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2622684099","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622684099?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:23","pubTimestamp":1774607034,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布公告，本集团已取得中国国家药品监督管理局有关乳酸钠林格冲洗液和布美他尼注射液 的药品生产注册批件，均属于化学药品第3类，视同通过一致性评价。本集团的乳酸钠林格冲洗液是国内企业首家获批，主要用于允许使用无菌电解质溶液的一般冲洗。诚如本公司日期为2026年3月16日的公告所载，本集团的布美他尼原料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)取得国家药监局有关乳酸钠林格冲洗液(3000ml)和布美他尼注射液 (2ml:1mg)的药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102191710","title":"石四药集团2025年度业绩大幅回落，毛利率与盈利双双承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1102191710","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102191710?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:09","pubTimestamp":1774584568,"startTime":"0","endTime":"0","summary":"石四药集团截至2025年12月31日止年度录得收入约41.65亿港元，同比减少27.8%。同时，产品以人民币计价也在一定程度上影响了港元折算收入。本年度毛利约17.31亿港元，同比下降40.5%，毛利率由50.4%降至41.6%，主要受产品单价与结构变化影响。整体来看，该公司在静脉输液与注射液业务方面的销量下滑叠加市场竞争加剧，导致收入和盈利出现显著下跌，毛利率也同步走低。公司表示将继续控制生产及管理成本，并加强研发投入与业务布局，以期带动后续业务表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128883887","title":"石四药集团将于2026年6月4日派发末期股息每股0.03港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1128883887","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128883887?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:06","pubTimestamp":1774584390,"startTime":"0","endTime":"0","summary":"石四药集团(02005)公告显示，公司董事局已建议派发截至2025年12月31日止年度之末期股息，每股0.03港元，须待股东于2026年5月15日批准后方可作实。\n\\n\\n\n根据公告，除净日定于2026年5月20日，股东于2026年5月21日16时30分前递交股份过户文件可获派息，记录日期亦为2026年5月21日。若获股东大会通过，该股息将于2026年6月4日派发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622814340","title":"石四药集团(02005)发布年度业绩 净利润约4.71亿港元 同比减少55.6% 末期息0.03港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814340","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622814340?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:05","pubTimestamp":1774584321,"startTime":"0","endTime":"0","summary":"2025年全年实现销售收入以人民币计约38.12亿元，同比减少27.6%;以港元计，全年销售收入约41.65亿港元，同比减少27.8%;同期毛利率约41.6%，同比下降8.8个百分点;实现净利润约4.71亿港元，同比减少55.6%。董事议决于2026年6月4日向于2026年5月21日名列本公司股东名册的股东派发末期息0.03港元╱股，全年共派息0.08港元╱股，同比减少54.3%。全年完成42个通用名52个品规的上市准入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"石四药集团(02005)发布年度业绩 净利润约4.71亿港元 同比减少55.6% 末期息0.03港元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620488622","title":"石四药集团(02005)：氯化钙获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2620488622","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620488622?lang=zh_cn&edition=full","pubTime":"2026-03-19 16:32","pubTimestamp":1773909153,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的氯化钙已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。氯化钙作为一种静脉注射液添加药物，主要用于治疗钙缺乏、手足搐搦症、维生素D缺乏症和过敏性疾患，以及用于镁中毒、氟中毒和心功能异常(高血钾、低血钙或钙通道阻滞引起)的解救。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619435161","title":"石四药集团(02005)：布美他尼已获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2619435161","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619435161?lang=zh_cn&edition=full","pubTime":"2026-03-16 12:14","pubTimestamp":1773634468,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，本集团的布美他尼已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。布美他尼是一种袢利尿剂，主要用于治疗与心力衰竭以及肾、肝功能失调相关的水肿，也用于预防急性肾功能衰竭及治疗高血压、高钾血症及高钙血症、稀释性低钠血症、抗利尿激素分泌过多症(SIADH)及急性药物毒物中毒等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)：布美他尼已获国家药监局批准登记成为在上市制剂使用的原料药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619162174","title":"石四药集团(02005)：大容量生理氯化钠溶液(3000ml:27g)已获国家药监局批准关联申报采用江苏博生医用新材料生产的三层共挤输液用管作为药包材","url":"https://stock-news.laohu8.com/highlight/detail?id=2619162174","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619162174?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:34","pubTimestamp":1773390849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，本集团的大容量生理氯化钠溶液(3000ml:27g)已获中国国家药品监督管理局批准关联申报采用江苏博生医用新材料股份有限公司(本集团内子公司)生产的三层共挤输液用管作为药包材。目前，由于冲洗液、透析液等大规格输液产品对安全性、稳定性及临床使用的特殊性有严格要求和标准，其所需的高性能输液袋软管全部依赖进口。本公司相信，此次获批标志着三层共挤输液用管已成功实现国产化替代，展现了本集团在药包材领域的自主创新突破，预期对本集团的业务带来正面影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191","159703"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619168224","title":"每日卖空追踪 | 石四药集团 03月12日卖空量成交33万股，卖空比例为8.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619168224","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619168224?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304227,"startTime":"0","endTime":"0","summary":"石四药集团北京时间03月12日，跌1.19%，卖空量成交33万股，较上一交易日减少77.88%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163332a6ba50c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163332a6ba50c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":-0.048},{"period":"3month","weight":-0.1987},{"period":"6month","weight":-0.2372},{"period":"1year","weight":-0.1584},{"period":"ytd","weight":-0.159}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0437},{"period":"3month","weight":-0.025},{"period":"6month","weight":-0.0011},{"period":"1year","weight":0.1567},{"period":"ytd","weight":0.0228}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.008314},{"month":2,"riseRate":0.52381,"avgChangeRate":0.02049},{"month":3,"riseRate":0.666667,"avgChangeRate":0.079064},{"month":4,"riseRate":0.47619,"avgChangeRate":0.031009},{"month":5,"riseRate":0.47619,"avgChangeRate":0.011037},{"month":6,"riseRate":0.5,"avgChangeRate":0.067908},{"month":7,"riseRate":0.35,"avgChangeRate":-0.027819},{"month":8,"riseRate":0.35,"avgChangeRate":-0.017769},{"month":9,"riseRate":0.3,"avgChangeRate":-0.04678},{"month":10,"riseRate":0.45,"avgChangeRate":-0.001982},{"month":11,"riseRate":0.65,"avgChangeRate":0.086372},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009169}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}